Platelets and restenosis

Journal of the American College of Cardiology

Volumn 35, Issue 3, 2000, Pages 555-562

  Chandrasekar, Baskaran ^a   Tanguay, Jean François ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOPEPTIN; ANTITHROMBOCYTIC AGENT; AURINTRICARBOXYLIC ACID; BROMOCRIPTINE; CALCIUM ANTAGONIST; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; GROWTH FACTOR RECEPTOR; ILOPROST; INDOMETACIN; NAFTIDROFURYL; NITRIC OXIDE DONOR; OLIGONUCLEOTIDE; PACLITAXEL; PEMIROLAST; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E1; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TICLOPIDINE; TRANILAST; TRAPIDIL; TROGLITAZONE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; DRUG TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RESTENOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; BLOOD PLATELETS; CELL DIVISION; CORONARY DISEASE; CORONARY VESSELS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET-DERIVED GROWTH FACTOR; RECURRENCE; TUNICA INTIMA;

EID: 0034163002     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00596-3     Document Type: Article

References (102)

1. Gruentzig A.R. Transluminal dilatation of coronary-artery stenosis. Lancet. 1:1978;263.
2. Dangas G., Fuster V. Management of restenosis after coronary intervention. Am Heart J. 132:1996;428-436.
3. Garratt K.N., Edwards W.D., Kaufmann U.P., Vlietstra R.E., Holmes D.R. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts analysis of tissue obtained from 73 patients by directional atherectomy . J Am Coll Cardiol. 17:1991;442-448.
4. Post M.J., Borst C., Kuntz R.E. The relative importance of arterial remodelling compared with intimal hyperplasia in lumen narrowing after balloon angioplasty. Circulation. 89:1994;2816-2821.
5. Currier J.W., Faxon D.P. Restenosis after percutaneous transluminal coronary angioplasty have we been aiming at the wrong target? J Am Coll Cardiol. 25:1995;516-520.
6. Markovitz J.H., Roubin G.S., Parks J.M., Bittner V. Platelet activation and restenosis after coronary stenting flow cytometric detection of wound-induced platelet activation . Coron Artery Dis. 7:1996;657-665.
7. Clowes A.W., Reidy M.A., Clowes M.M. Kinetics of cellular proliferation after arterial injury smooth muscle cell growth in the absence of endothelium . Lab Invest. 49:1983;327-333.
8. Steele P.M., Chesebro J.H., Stanson A.W., et al. Balloon angioplasty natural history of the pathophysiological response to injury in a pig model . Circ Res. 57:1985;105-112.
9. Moore S., Friedman R.J., Singhal D.P., et al. Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost. 35:1975;70-81.
10. Fox JEB. Platelet biology and retenosis. Restenosis Summit VIII, the Cleveland Clinic Heart Center. May 1996, p 234.
11. Casscells W. Smooth muscle cell growth factors. Prog Growth Factor Res. 3:1991;177-206.
12. Uchida K., Sasahara M., Morigami N., et al. Expression of platelet derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis. 124:1996;9-23.
13. Bornfeldt K.E., Raines E.W., Nakano T., et al. Insulin-like growth factor-1 and platelet derived growth factor-BB induce direct migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J Clin Invest. 93:1994;1266-1274.
14. Grant M.B., Wargovich T.J., Ellis E.A., et al. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells a potential treatment for restenosis . Circulation. 89:1994;1511-1517.
15. Pazin M.J., Williams L.T. Triggering signalling cascades by receptor tyrosine kinases. Trends Biochem Sci. 17:1992;374-378.
16. Grant M.B., Wargovich T.J., Bush D.M., et al. Expression of IGF-1, IGF-1 receptor and TGF-beta following balloon angioplasty in atherosclerotic and normal rabbit iliac arteries an immunocytochemical study . Regul Pept. 79:1999;47-53.
17. Nabel E.G., Shum L., Pompili V.J., et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA. 90:1993;10759-10763.
18. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 96:1997;2280-2286.
19. 2-antagonism (CARPORT) study . Circulation. 84:1991;1568-1580.
20. Kumar A., Hoover J.L., Simmons C.A., et al. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 96:1997;4333-4342.
21. 2 receptor antagonists in the prevention of intimal thickening. Eur J Pharmacol. 362:1998;53-59.
22. Loppnow H., Bil R., Hirt S., et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood. 91:1998;134-141.
23. Stoll L.L., Spector A.A. Interaction of platelet-activating factor with endothelial and vascular smooth muscle cells in coculture. J Cell Physiol. 139:1989;253-261.
24. Herbert J.M., Laplace M.C., Mares A.M., Dol F. Platelet-activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury. J Lipid Mediat Cell Signal. 12:1995;49-57.
25. Walsh P.N., Schmaier A.H. Platelet-coagulant protein interactions. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and Thrombosis Basic Principles and Clinical Practice . 3rd ed. 1994;629-651 J.B. Lippincott, Philadelphia.
26. Maruyama I., Shigeta K. Regulation of the endothelial function by thrombomodulin and/or thrombin receptor. Rinsho Ketsueki. 35:1994;234-237.
27. McNamara C.A., Sarembock I.J., Gimple L.W., et al. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cell by a proteolytically activated receptor. J Clin Invest. 91:1993;94-98.
28. Wilner G.D., Danitz M.P., Mudd M.S., et al. Selective immobilization of alpha-thrombin by surface-bound fibrin. J Lab Clin Med. 97:1981;403-411.
29. Marmur J.D., Merlini P.A., Sharma S.K., et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol. 24:1994;1484-1491.
30. Bach R., Jung F., Kohsiek I., et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thromb Res. 74:1994;S55-S67.
31. Smyth D.W., Martin J.F., Michalis L., et al. Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest. 23:1993;361-367.
32. Chronos N.A., Goodall A.H., Wilson D.J., et al. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation. 88:1993;2035-2044.
33. Gutensohn K., Beythien C., Bau J., et al. Tantalum stent induce expression of GMP140 and GP53 on platelets after contact in an in vitro model. Beitr Infusionsther Transfusionsmed. 33P:1996;61-65.
34. Sterner G., Carlson J., Ekberg G. Raised platelet levels in diabetes mellitus complicated with nephropathy. J Intern Med. 244:1998;437-441.
35. Rabini R.A., Staffolani R., Fumelli P., et al. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia. 41:1998;101-104.
36. Himmelfarb J., Holbrook D., McMonagle E., Ault K. Increased reticulated platelets in dialysis patients. Kidney Int. 51:1997;834-839.
37. Broijersen A., Hamsten A., Eriksson M., et al. Platelet activity in vivo in hyperlipoproteinemia - importance of combined hyperlipidemia. Thromb Haemost. 79:1998;268-275.
38. Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;247-251.
39. Kozai T., Shimokawa H., Fukumoto Y., et al. Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo. J Cardiovasc Pharmacol. 29:1997;536-545.
40. Abe J., Deguchi J., Takuwa Y., et al. Tyrosine phosphorylation of platelet derived growth factor β receptors in coronary artery lesions implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris . Heart. 79:1998;400-406.
41. Berk B.C., Alexander R.W., Brock T.A., et al. Vasoconstriction a new activity of platelet-derived growth factor . Science. 232:1986;87-90.
42. Teirstein P.S., Massullo V., Jani S., et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 336:1997;1697-1703.
43. King S.B. III, Williams D.O., Chougule P., et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty results of the Beta Energy Restenosis Trial (BERT) . Circulation. 97:1998;2025-2030.
44. Muller D.W.M. The role of proto-oncogenes in coronary restenosis. Prog Cardiovasc Dis. 40:1997;117-128.
45. Varenne O., Pislaru S., Gillijns H., et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 98:1998;919-926.
46. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 318:1988;1714-1719.
47. Kastrati A., Schuhlen H., Hausleiter J., et al. Restenosis after coronary placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial . Circulation. 96:1997;462-467.
48. Moussa I., Oetgen M., Roubin G., et al. Effectiveness of clopidogrel and aspirin versus ticlopidine versus aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 99:1999;2364-2366.
49. Coller B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 76:1985;101-108.
50. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
51. Topol E.J., Califf R.M., Weisman H.F., et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis results at six months . Lancet. 343:1994;881-886.
52. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92.
53. 3 blockade with percutaneous coronary intervention. JAMA. 278:1997;479-484.
54. Topol E.J., Serruys P.W. Frontiers in interventional cardiology. Circulation. 98:1998;1802-1820.
55. Reverter J.C., Beguin H., Kessels H., et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis.' . J Clin Invest. 98:1996;863-874.
56. Jones J.I., Prevette T., Gockerman A., Clemmons D.R. Ligand occupancy of the αvβ3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor 1. Proc Natl Acad Sci USA. 93:1996;2482-2487.
57. Brooks P.C., Clark R.A.F., Cheresh D.A. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 264:1994;569-571.
58. Matsuno H., Stassen J.M., Vermylen J., Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 90:1994;2203-2206.
59. Mickelson J.K., Nadir Ali M., Kleiman N.S., et al. Chimeric c7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 33:1999;97-106.
60. Inoue T., Sakai Y., Morooka S., et al. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 28:1996;1127-1133.
61. 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 95:1998;10134-10139.
62. Simon D.I., Xu H., Ortlepp S., et al. 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 17:1997;528-535.
63. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
64. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
65. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
66. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 100:1999;799-806.
67. Deitch J.S., Williams J.K., Adams M.R., et al. Effects of β3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. Arterioscler Thromb Vasc Biol. 18:1998;1730-1737.
68. Take S., Matsutani M., Ueda H., et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 79:1997;1097-1099.
69. Tsuchikane E., Fukuhara A., Kobayashi T., et al. Impact of cilastazol on restenosis after percutaneous transluminal coronary angioplasty. Circulation. 100:1999;21-26.
70. Schwarzacher S.P., Lim T.T., Wang B., et al. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation. 95:1997;1863-1869.
71. Matsuno H., Kozawa O., Niwa M., et al. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost. 79:1998;865-871.
72. Banning A., Brewer L., Wendt M., et al. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries effect on platelet deposition and neointima formation . Thromb Haemost. 77:1997;190-196.
73. El-Gamal B.A., Pfliegler G., Crawford N. Effect of platelet encapsulated iloprost on platelet aggregation and adhesion to collagen and injured blood vessels in vitro. Thromb Haemost. 68:1992;606-614.
74. Barradas M.A., Jadroop I.A., Mikhailidis D.P. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta. 230:1994;157-167.
75. Vissinger H., Husted S.E., Kristensen S.D., Nielsen H.K. Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid. Angiology. 44:1993;633-638.
76. Tiell M.L., Sussmann I., Gordon P.B., Sanders R.N. Suppression of fibroblast proliferation in vitro and of neointimal hyperplasia in vivo by the triazolopyrimidine, trapidil. Artery. 12:1983;33-50.
77. Gesualdo L., Di Paolo S., Ranieri E., et al. Trapidil inhibits human mesangial cell proliferation effect of PDGF-beta receptor binding and expression . Kidney Int. 46:1994;1002-1009.
78. Mest K.J. Trapidil a potent inhibitor of platelet aggregation . J Drug Dev. 3:1990;143-149.
79. Serruys P.W., Banz K., Darcis T., et al. Results of a meta-analysis of trapidil, a PDGF inhibitor a sufficient reason for a second look to the pharmacological approach to restenosis . J Invas Cardiol. 9:1997;505-512.
80. Serruys P.W., Pieper M., vd Bos A.A., et al. TRAPIST study a randomized double blind study to evaluate the efficacy of trapidil on restenosis after successful elective coronary stenting (abstr) . Circulation. 98:(Suppl I):1998;I-362.
81. Wagner R., Nishikura K. Cell cycle expression of RNA duplex unwinding activity in cells. Mol Cell Biol. 8:1988;770-777.
82. Bennett M.R., Schwartz S.M. Antisense therapy for angioplasty restenosis some critical considerations . Circulation. 92:1995;1981-1993.
83. Sirois M.G., Michael S., Edelman E.R. Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation. 95:1997;669-676.
84. Cool D.E., Anderssen P.R., Tonks N.K., et al. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosine-phosphatase. Proc Natl Acad Sci USA. 89:1992;5422-5426.
85. Dahring T.K., Lu G.H., Hamby J.M., et al. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 281:1997;1446-1456.
86. Kovalenko M., Gazit A., Bohmer A., et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114.
87. Law R.E., Meehan W.P., Xi X.P., et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1996;1897-1905.
88. Mullins D.E., Hamud F., Reim R., Davis H.R. Inhibition of PDGF receptor binding and PDGF-stimulated biological activity in vivo by 2-bromomethyl-5-chlorobenzene sulfonylphthalimide. Arterioscler Thromb. 14:1994;1047-1055.
89. Konneh M.K., Rutherford C., Li S.R., et al. Vitamin E inhibits the intimal response to balloon catheter injury in the carotid artery of the cholesterol-fed rat. Atherosclerosis. 113:1995;29-39.
90. Ross R. Platelet derived growth factor. Lancet. 1:1989;1179-1182.
91. Hillegass W.B., Ohman E.M., Leimberger J.D., Califf R.M. A meta-analysis of randomised trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol. 73:1994;835-839.
92. Thaulow E., Jorgensen B. Clinical promise of calcium antagonists in the angioplasty patient. Eur Heart J. 18:(Suppl B):1997;B21-B26.
93. Miyazawa N., Umemura K., Kondo K., Nakashima M. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J Cardiovasc Pharmacol. 30:1997;157-162.
94. Valius M., Kazlauskas A. Phospholipase C and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell. 73:1993;321-334.
95. Ohsawa H., Noike H., Kanai M., et al. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 136:1998;1081-1087.
96. Zhang Y., Cincotta A.H. Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation. Atherosclerosis. 133:1997;37-44.
97. Kariya K.I., Kawahara Y., Tsuda T., et al. Possible involvement of protein kinase C in platelet derived growth factor-stimulated DNA synthesis in vascular smooth muscle cells. Atherosclerosis. 63:1987;251-255.
98. Cao W., Mohacsi P., Shorthouse R., et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis inhibition of fibroblast growth factor and platelet derived growth factor action and antagonism of rapamycin by FK506 . Transplantation. 59:1995;390-395.
99. 1 on intimal thickening following photochemically induced endothelial injury in the rat femoral artery. Atherosclerosis. 130:1997;11-16.
100. Koyama N., Morisaki N., Saito Y., Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 267:1992;806-812.
101. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
102. Axel D.I., Kunert W., Goggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 96:1997;636-645.